Role of zinc in maternal and child mental health1–4

Ann M DiGirolamo and Manuel Ramirez-Zea

ABSTRACT
Mental health problems in women, children, and adolescents are a significant public health issue. Given current barriers to the effective treatment of these problems, researchers are looking to the field of nutrition for potential alternatives to better understand and address mental health issues. The purpose of this article was to review current evidence on the relation between zinc and mental health disorders with a focus on 2 mental health problems that commonly affect women and children: depression and attention-deficit hyperactivity disorder (ADHD). A literature search of the databases Medline and PsychInfo was conducted with the use of key terms. The review included articles from 1975 to May 2008, but focused on articles published in recent years. Relations between zinc concentrations and behavior in animals; the relation between zinc deficiency, depression, and ADHD in patient and community samples; and the potential biological mechanisms for these relations were explored. The data support a relation between low concentrations of zinc and mental health problems, especially in at-risk populations. Evidence for the potential use of zinc in treating mental health problems comes mainly from patient populations and is strongest when zinc is given in combination with pharmacologic treatment. Less conclusive evidence exists for the effectiveness of zinc alone or in general community samples. Recommendations for further research in this area are provided. Am J Clin Nutr 2009;89(suppl):940S–5S.

INTRODUCTION
Mental health problems in women, children, and adolescents are a significant public health issue. Maternal depression is very common globally, the prevalence of which ranges from 15% in the United States to 35% in low-income South African mothers (1–5). Furthermore, the average prevalence of maternal postpartum depression within 6–8 wk after childbirth is 13% in the general population (6). The high prevalence of maternal depression is of concern because of its effects on maternal physical and emotional well-being (7) and because of the link with deficient childcare, negative caregiver/child interactions, child growth impairment, and increased medical problems, accidents, and emotional problems among children (8–10).

One in 10 children and adolescents in the United States have a mental illness severe enough to significantly impair functioning (11, 12), with worldwide prevalence rates for child and adolescent mental disorders of $>$20% (13, 14). Examples of common childhood disorders include attention-deficit hyperactivity disorder (ADHD), depression, and anxiety. The World Health Organization suggests that childhood neuropsychiatric disorders will increase worldwide by $>$50% by 2020, with these disorders becoming 1 of 5 of the most common causes of morbidity, mortality, and disability in children (14).

Fewer than 1 in 5 children currently receive the necessary treatment services for these disorders (11), and the situation in developing countries may be worse for both women and children (14). Although there has been significant progress in identifying effective treatments for adults, more information is needed, particularly for women of reproductive age and children. Psychotherapy is costly, requires time and commitment from both children and parents, and often is not available or acceptable, particularly in developing countries. Pharmacotherapy is also costly, is often unavailable, and has potential side effects for children and for women who may be pregnant (15, 16). In addition, problems of awareness, access, lack of resources, and stigma regarding mental health services may prevent women and children from receiving the necessary treatment of mental health problems, especially in developing countries where these problems are more pronounced. Therefore, we need alternative treatments or preventive methods that are readily accessible and acceptable to populations nationally and internationally.

Researchers have begun to look to the field of nutrition for potential alternatives to better understand and address mental health issues. Compelling evidence for the role of micronutrients in mental health has come from studies focusing on the role of zinc in depression and ADHD, disorders that are common among women and children, respectively. Studies in animals and humans have shown relations between low zinc concentrations and symptoms of depression and ADHD and have suggested the potential effectiveness of zinc supplementation for these disorders. This information is important given the large number of populations at risk of zinc deficiency, both nationally and internationally, particularly in developing countries. Pharmacotherapy is also costly, is often unavailable, and has potential side effects for children and for women who may be pregnant (17, 18).

The purpose of this article was to review evidence on the relation between zinc deficiency and mental health with a focus...
on 2 mental health disorders that commonly affect women and children: depression and ADHD. This article has 3 sections. The first section reviews animal studies of the relation between zinc concentrations and behavior, as an analog to mental health disorders. The second section reviews potential biological mechanisms for the relation between zinc deficiency and depression and ADHD. The final section reviews human studies conducted in patient and community samples experiencing depression or ADHD. The databases Medline and PsychInfo were searched with the use of the following key terms: zinc, zinc deficiency, zinc supplementation, intervention, treatment, mental health, depression, anxiety, ADHD, stress, mood, and behavior. The review included articles from 1975 to May 2008, but the focus was on the more recent articles and on disorders that predominantly affect women and children; however, studies of other populations (eg, men and the elderly) were included in an attempt to shed light on the relation between zinc and these mental health issues.

**ANIMAL STUDIES**

Many studies using rats, mice, and monkeys have examined relations between zinc concentrations and behavior as analogs to depression, anxiety, aggression, and attention problems. These studies fall into 2 categories: 1) those that examined behavioral outcomes after zinc deficiency, and 2) those that assessed the antidepressant-like properties of zinc. Several studies have reported that zinc deficiency is associated with low levels of activity, lethargy, apathy, and attention in rats and rhesus monkeys (19–22). For example, studies in prepubertal monkeys with moderate zinc restriction found lower spontaneous motor activity and reduced performance of tasks that require visual attention (21–23). Others have noted more aggressive behavior in isolated zinc-deficient mice than in isolated control mice (24) and anxiety-like behavior (eg, decreased time spent in the open arms of a maze test) in young rats with serum zinc concentrations 50% of those of control rats after a zinc-deficient diet (25, 26). Similarly, studies using animal models of psychological stress have suggested that concentrations of zinc in mice exposed to both acute and chronic stress situations were significantly lower than those in a control group (27), and evidence in rats suggests that zinc deficiency may lower the body’s adaptability to stress (28).

Experimental studies in mice and rats have examined reduced locomotor activity or fighting behavior during exposure to stress or the insecticide malathion, as an analog for depression, and found that zinc supplementation induced antidepressant-like effects, reductions in immobility time during forced-swim tests, and increases in fight responses previously inhibited during stress (29–31). Effects were seen for zinc alone, but the effects were augmented when zinc was paired with an antidepressant such as imipramine (30).

**POTENTIAL BIOLOGICAL MECHANISMS**

Zinc is a trace element essential for brain development and central nervous system function (32). More than 200 enzymes are zinc metalloenzymes, requiring zinc for normal neuronal development (32). In addition, zinc is present in synaptic vesicles in a subgroup of glutamatergic neurons in the brain. This form of zinc may modulate responses at receptors for a number of different neurotransmitters, both excitatory and inhibitory, including the N-methyl-D-aspartate (NMDA) and γ-aminobutyric acid (GABA_\text{A}) receptors involved in depression and anxiety (33). Because of the importance of zinc metabolism in the brain, zinc deficiency has been associated with neurological dysfunction and human brain pathology (32, 33).

Several researchers have attempted to identify the mechanisms through which zinc may be involved in mental health disorders such as depression and ADHD. One suggested pathway for depression is through zinc’s effects on neurotransmitter responses at the NMDA receptors (29, 33, 34). For example, studies have suggested that NMDA glutamate receptors in depressed patients may be supersensitive, with dysregulation of glutamate often described in depression (35). Glutamate, the major neurotransmitter in excitatory hippocampal pathways, may overstimulate the NMDA pathway in sensitive individuals, leading to aberrant brain biochemical activity or brain cell atrophy and loss associated with depression (36–39). Studies, including double-blind trials, have shown that NMDA receptor antagonists dampen NMDA receptor function and exhibit antidepressant properties (40–42). Zinc is a very potent inhibitor of the NMDA receptor complex, with recent studies suggesting that zinc can induce an antidepressant-like effect in animals and may enhance the effect of other antidepressant medications such as imipramine (29, 30, 43). Others have suggested that zinc may exhibit an antidepressant effect through direct or indirect activation of adenosine A_1 and A_2A receptors (44) or a possible up-regulation of neuroprotective effectors (eg, glutathione) (45).

Several mechanisms have been suggested to explain the relation between zinc and ADHD symptoms, possibly through alterations in the neurotransmitters dopamine and serotonin. Zinc is important for the production and modulation of melatonin, which regulates dopamine function (46–48), and for the conversion of dietary pyridoxine to its active form, pyridoxal phosphate, which is necessary for the conversion of tryptophan to serotonin (49). Both the dopamine and serotonin neurotransmitter systems appear to be involved in ADHD (50). Supplementation with zinc may resolve the reduction in melatonin and serotonin synthesis and improve ADHD symptoms, such as impulsivity (46, 49, 51). Zinc may also influence the N2 wave in the frontal and parietal regions of the brain, with effects seen on information processing and possibly on the inhibitory processes of children with ADHD (52).

Dopamine and serotonin neurotransmitter systems may be implicated in both ADHD and depression (50, 53), which suggests that there may be a common pathway whereby zinc is involved in both disorders. More research is needed to delineate the actual mechanisms involved, to better understand the possibility of common pathways between the 2 disorders, and to determine potential treatment implications.

**DEPRESSION**

**Human studies of association**

*Clinical patient samples*

Several studies in clinical patient samples (ie, diagnosed major depression) have shown lower zinc concentrations in patients than in control subjects. Patients with depression have lower plasma or serum zinc concentrations than do nondepressed patients, and
some studies suggest that low serum zinc may be a marker of treatment resistance in depression (54–56). Whether low zinc concentrations are a result of depression, indicating poor appetite, reduced dietary intake, or an immune/inflammatory response that occurs in depression, or actually result in or exacerbate a depressive disorder is still unclear (54, 55).

Community samples

Studies of associations among community samples have been fairly consistent in reporting associations between low zinc concentrations and depression or emotional difficulties. Most studies have involved postpartum women and the elderly. Among women, lower serum zinc concentrations have been associated with the severity of postpartum depressive symptoms (57). Several studies that examined the role of zinc status in the elderly, mainly in Europe through the Zincage Study, have suggested that zinc is important in reducing stress in the elderly. Lower plasma zinc concentrations were related to poorer results for several psychological variables, including measures of cognitive status, mood, and perceived stress, especially in areas with low zinc intakes and a limited variety of foods containing zinc (58, 59). An additional study from Italy noted a relation between the concentration of albumin (as an indicator of zinc status) and depression; 71% of participants with an albumin deficiency had a higher score on a measure of depression than did the 29% of participants with a normal albumin value (60). However, another study in an aging European sample found no association between mood and zinc status; zinc status was within the normal range, which suggests that the potential influence of zinc on mood may be small and undetectable when zinc status is within normal limits (61).

Intervention studies

Clinical patient samples

Intervention studies in clinical samples that examined the role of zinc in depression have focused on patients with major unipolar depression and anorexia nervosa. These studies, although conducted in fairly small sample sizes, provide strong evidence that zinc may play a role in depression and may be helpful in treatment. In a study of male and female patients aged 25–57 y who met the criteria for major unipolar depression, 6 were treated with 25 mg Zn/d for 12 wk and 8 were treated with a placebo; both groups were treated with standard antidepressant therapy (34). Scores on depression inventories were obtained at baseline and 2, 6, and 12 wk after treatment; those in the zinc-supplemented group had significantly lower depression scores after 6 and 12 wk of supplementation than did the placebo group (antidepressant but no zinc). This finding suggests that zinc may enhance the effects of antidepressant treatments on symptoms of depression (34). Recent reviews by Nowak et al (62) and Levenson (63) concluded that zinc has an important role in both the psychopathology and treatment of depression, which suggests that zinc has antidepressant properties.

Randomized controlled trials of zinc supplementation in patients with anorexia nervosa have suggested that zinc therapy enhances the rate of recovery in anorexia by increasing weight gain and improving levels of depression and anxiety (64–66). For example, in a double-blind randomized controlled trial in adolescents with anorexia nervosa, patients were randomly assigned to a zinc supplementation group (50 mg elemental zinc daily for 6 mo in the form of zinc sulfate) or a placebo group. Both groups received the conventional therapeutic regimen for anorexia of psychotherapy, behavior modification, and nutritional rehabilitation. At the end of 6 mo, significant decreases in symptoms of both depression and anxiety were found in the adolescents supplemented with zinc; similar decreases were not found for the placebo group. There was no change in serum zinc concentrations for either group (65).

Community samples

We found no intervention studies that specifically examined the role of zinc in depression among community samples. Large population-based studies with community samples that examined the effects of zinc supplementation on emotional, psychosocial, and behavioral outcomes in infants and children have produced mixed results. Most studies have been conducted in at-risk populations of children. Several studies examined activity levels and behavior in infants and preschool children. Infants in rural Guatemala supplemented with zinc for 7 mo sat up more frequently, played more, and cried or whined less than did an unsupplemented group (67). A similar zinc supplementation trial among preschool children in India showed significantly greater activity levels among the supplemented children than among control subjects (68). Several studies of zinc supplementation among infants in developing countries have noted positive effects of zinc supplementation on exploratory behavior and behaviors such as responsiveness, emotional tone, activity level, cooperation, and vocalization (69, 70). Other studies found no direct effects of zinc on infant behavior (71–73). This evidence is important to consider when examining the relation between zinc and depression, as sad or irritable affect, psychomotor retardation, and loss of energy are all symptoms related to depression in children and adults.

ADHD

Human studies of association

Clinical patient samples

Lower blood zinc concentrations have been found in children with ADHD than in control subjects in several countries (52, 74–76), with some suggestion that zinc concentrations may be related to the severity of symptoms. For example, Arnold et al (77) found that serum zinc concentrations were negatively correlated ($r = −0.45$) with parent-teacher ratings of inattention in US children with ADHD; however, no relation was found with ratings of hyperactivity-impulsivity. A review by Arnold and DiSilvestro (48) reports numerous controlled studies with cross-sectional evidence of lower zinc tissue concentrations (eg, serum, red blood cells, hair, urine, and nails) in children with ADHD than in normal control subjects and compared with population norms (74–76, 78, 79).

Community samples

Although they did not specifically examine the relation between zinc and ADHD symptoms, several studies in community samples of children have examined the relation between zinc status and behavioral or emotional problems that often coexist in children with ADHD. Zinc intake based on probed oral recall and weighing
of food portions was positively related to social behavior in girls and to activity level in boys in a sample of Egyptian children aged 7–10 y (80), and plasma zinc concentrations were inversely related to teacher ratings of anxiety in 3–5-y-old boys in the Head Start program (81). In the latter study, zinc explained 39% of the variance in anxiety, but was not related to ratings of sociability or aggressive behavior.

**Intervention studies**

**Clinical patient samples**

Several studies have examined the potential treatment effects of zinc on ADHD symptoms in children (49, 82), with some suggestion that, as in depression, zinc may enhance the treatment effects of traditional treatments for ADHD, such as methylphenidate (also known as ritalin). Zinc supplementation in a small group of Iranian children with ADHD aged 5–11 y enhanced the effects of methylphenidate; children in the zinc supplementation plus methylphenidate group showed a significantly greater improvement in parent- and teacher-rated ADHD symptoms than did the placebo group who received methylphenidate alone (82). Similarly, Arnold et al (79, 83) noted that the response of boys aged 6–12 y with ADHD to amphetamine treatment was related to zinc concentration; stronger effects were observed in the children with adequate zinc status. The one controlled study in Turkey that examined the potential treatment effects of zinc alone on ADHD noted significant decreases in some ADHD symptoms (eg, hyperactivity and impulsivity) in children supplemented with 150 mg Zn as zinc sulfate for 12 wk as compared with the placebo group (49); however, this study had a high dropout rate, used rather high doses of zinc, and the outcome variables may not have been comparable with those in other ADHD trials because the measures were locally developed or adapted from English (48). More controlled trials are needed before the use of zinc supplementation for the treatment of ADHD can be recommended.

**Community samples**

As for depression, we found no intervention studies that specifically examined the role of zinc in addressing ADHD symptoms among community samples. However, in community studies of older children and adolescents, zinc supplementation did not appear to produce significant and consistent improvements in psychosocial or behavioral functioning (84, 85). In a sample of first-grade Mexican children exposed to lead, there were no effects of zinc supplementation on mean changes in scores from behavioral rating scales over time (ie, 6 mo), but children who received zinc had a higher likelihood of no longer receiving clinically significant teacher ratings of oppositional behaviors (84). Similarly, in a 10-wk fruit juice zinc fortification program among US adolescents, psychosocial functioning was unrelated to zinc treatment, except that conduct problems increased by 10% in girls who received placebo; no change was observed in the zinc-treated girls (85).

Given the large prevalence of zinc deficiency in many of these at-risk populations and the evidence suggesting a relation between zinc, depression, and ADHD, more controlled community-based studies of zinc supplementation are needed to address the potential of zinc to enhance psychological functioning and improve or prevent mental health problems. The authors are currently conducting a community-based randomized controlled trial of zinc supplementation in 722 school-age children in Guatemala, an area at risk of zinc deficiency, to assess the effects of zinc supplementation for 6 mo compared with placebo on the mental health and school performance of children.

**CONCLUSIONS**

Support exists from both animal and human studies for a relation between low concentrations of zinc and certain mental health problems (eg, depression and ADHD), especially in at-risk populations; some support exists for the improvement of these mental health problems with zinc treatment. Evidence for the treatment potential of zinc comes mainly from patient populations and is strongest when zinc is given in combination with pharmacologic treatments. There is less conclusive evidence of the effectiveness of zinc alone or of the effectiveness of zinc on mental health and behavior among general community samples, in whom fewer studies have been conducted.

More research is needed to understand whether low zinc status is a cause or an effect of mental health problems, with more controlled studies examining the treatment potential and preventive effects of zinc supplementation, especially in women and children. We need to better understand the neurobiological mechanisms underlying the role of zinc in depression and ADHD and to examine whether there are common pathways for the role of zinc in these and other mental health disorders.

Children of depressed mothers are at risk of emotional and behavioral problems, although the pathways underlying this relation have not been clearly defined (8, 86). For example, in the face of depressed mothers, children may have difficulty adapting to their environment or may develop a cognitive vulnerability to mental health problems through exposure to highly critical, hostile, and inconsistent maternal behavior. Alternatively, children may be vulnerable to developing depression and other disorders because of a biological predisposition or a hyperreactive physiologic response to stress (86–89). Zinc deficiency may play a role in mental disorders in both parents and children through its possible effects on neurotransmitters and the developing brain. Prospective studies are needed to evaluate the role of zinc deficiency in the development of ADHD, depression, and other childhood disorders in children of mothers who are depressed.

Several of the studies reviewed in this article used age- and sex-matched control subjects (54, 56, 65) or controlled for potential confounding variables such as sex, age, and income (67, 77); however, this has not been done consistently. Very few studies have focused on women of childbearing age to examine the potential treatment or preventive effects of zinc for depression, especially postpartum depression. Childbearing women are especially vulnerable to the adverse effects of poor nutrition on mood because pregnancy and lactation are major nutritional stressors (90). More studies are needed in older children and adolescents to better determine the effects of zinc on the mental health and behavior in this group, especially among children at risk of mental health problems and zinc deficiency. In addition, evidence suggests that zinc deficiency may affect cognitive development in children by decreasing activity, increasing emotional behavior, and impairing memory and the capacity to learn (91). Finally, given the cost and potential risks associated with many psychiatric
medications, especially in children and pregnant or lactating women, further exploration of zinc’s role in augmenting the effects of certain medications is recommended, which may result in lower doses of medication being needed. Because mental health problems continue to be a significant public health issue, future research is needed to explore the potential role of zinc and other micronutrients in mental health and to consider whether promoting a balanced diet rich in micronutrients, such as zinc, is an effective way to improve mental health and reduce the burden of neuropsychiatric disorders. (Other articles in this supplement to the Journal include references 92–97.)

We especially thank Maureen Black and Usha Ramakrishnan, Chairs of the symposium, for their review of the manuscript and excellent feedback.

The authors’ responsibilities were as follows—AMD: participated in the data collection, the review of the literature, and the writing and reviewing of the manuscript; and MR-Z: participated in the data collection and the review of the literature, critically reviewed the manuscript, and provided feedback. No conflicts of interest existed for either AMD or MR-Z.

REFERENCES


